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Background: Methylation of HIN-1 is associated with poor outcomes in patients with ovarian clear cell carcinoma
(OCCC), which is regarded to be an aggressive, chemo-resistant histological subtype. This study aimed to evaluate
whether 5-aza-2-deoxycytidine (5-aza-2-dC) can reverse methylation of the HIN-1 gene to restore chemo-sensitivity
of OCCC and the possible mechanism.
Methods: In vitro flow cytometric analysis and evaluation of caspase-3/7 activity of paclitaxel-sensitive and resistant
OCCC cell lines were performed. Methylation status and expression changes of HIN-1 in the OCCC cell lines treated
with 5-aza-2-dC were evaluated, and immunohistochemical staining of HIN-1 in OCCC tissues was performed. In
vivo tumor growth with or without 5-aza-2-dC treatment was analyzed, and Western blotting of AKT-mTOR
signaling-related molecules was performed.
Results: G2-M phase arrest was absent in paclitaxel-resistant OCCC cells after treatment with the cytotoxic drug.
The caspase activities of the chemo-resistant OCCC cells were lower than those of the chemo-sensitive OCCC cells
when treated with paclitaxel. Methylation of HIN-1 was noted in paclitaxel-resistant OCCC cell lines and cancerous
tissues. 5-aza-2-dC reversed the methylation of HIN-1, re-activated the expression of HIN-1, and then suppressed
the in vivo tumor growth of paclitaxel-resistant OCCC cells. Immunoblotting revealed that phospho-AKT473 and
phospho-mTOR were significantly increased in HIN-1-methylated paclitaxel-resistant OCCC cell lines. However, the
expressions of phospho-AKT at Ser473 and Thr308 and phospho-mTOR decreased in the OCCC cells with a high
expression of HIN-1.
Conclusions: Demethylating agents can restore the HIN-1 expression in paclitaxel-resistant OCCC cells through
the HIN-1-AKT-mTOR signaling pathway to inhibit tumor growth.
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Ovarian carcinoma is the fourth most common cause
of cancer death among women in the United States [1].
Cytoreductive surgery followed by platinum-based
chemotherapy is the standard initial treatment and has
improved survival in patients with ovarian cancer [2].
Recently, ovarian clear cell carcinoma (OCCC) has become
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The overall incidence of OCCC has been reported to be
higher in Taiwan and Japan [4–6].
The combination of paclitaxel and platinum, recognized
as the gold standard regimen for ovarian cancer [7], is
used to treat patients with all subtypes of ovarian neo-
plasms including OCCC. Compared to ovarian serous
carcinoma, OCCC is relatively resistant to platinum or
taxane-based chemotherapy, and this chemo-resistance
is associated with a lower response rate to chemotherapy
and a poor prognosis [5, 6, 8, 9]. For second-line or salvage
treatment, the response rate for recurrent or refractory
OCCC is far lower than that for other histological tumors,istributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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sponse rate is lower than 10 % [10]. Therefore, in order to
improve the survival of patients with OCCC, the develop-
ment of novel treatment strategies for both first-line and
salvage treatment for recurrent disease is urgently needed.
To achieve this goal, the identification of targets associated
with chemo-resistance and elucidation of the molecular
mechanisms of this process are urgently required.
Candidate DNA methylation drivers of acquired cisplatin
resistance in ovarian cancer identified by methylome and
expression profiling has been reported recently [11]. Data
on potential key drivers of chemo-resistance in OCCC that
are silenced by DNA methylation are limited, and further
evaluation as to their potential as therapeutic targets for
drug resistance is needed. Preclinical and clinical studies
strongly support the use of combination regimens, and
have shown that the hypomethylating agents azacitadine
and decitabine can restore platinum sensitivity in chemo-
resistant ovarian cancer cell lines, xenografts, and patients
with ovarian cancer [12–15]. However, the proof of concept
of the therapeutic effect in parental or resistant OCCC
in vitro and in vivo has not yet been established.
We hypothesized that there may be a subset of epigen-
etic changes causally associated with the acquisition of
chemo-resistance in OCCC. In order to identify the epi-
genetically altered genes driving paclitaxel resistance in
OCCC, we analyzed acquired DNA methylation changes
in a human paclitaxel-resistant OCCC cell line, and
expression changes associated with acquired resistance
or following resensitization with demethylating agents.
Although target therapies are currently used in many
cancers, the molecular pathogenesis of chemo-resistance in
OCCC is still unclear. We recently reported that methyla-
tion of HIN-1 promoter is a novel epigenetic biomarker as-
sociated with poor outcomes in patients with OCCC, and
that the ectopic expression of the HIN-1 gene increases
paclitaxel sensitivity partly through the Akt pathway [16].
Therefore, the aim of this study was to examine whether
5-aza-2-dC could reverse methylation of the HIN-1
gene and regulate the AKT/mTOR signaling pathway, and
then restore the chemo-response to paclitaxel in OCCC.
Methods
Cell lines and cultures
ES2 and TOV21G cell lines were obtained from the Ameri-
can Type Culture Collection. All cells were maintained in a
humidified atmosphere containing 5 % CO2 at 37 °C. ES-2
cells were grown in McCoy’s 5A medium with 10 % FBS,
and TOV21G maintained in MCDB 105/medium 199 sup-
plemented with 10 % heat-inactivated fetal bovine serum.
Establishment of chemo-resistant tumor cell lines
Paclitaxel-resistant ES-2 and TOV21G tumor cell lines
were developed by continuous exposure to paclitaxel.Briefly, ES-2 and TOV21G cells were exposed to increasing
concentrations of paclitaxel, with an initial concentration
of 0.001 μM. When the tumor cells regained exponential
growth after paclitaxel treatment, the concentration of
paclitaxel was doubled until the concentration reached
0.2 μM. The resulting paclitaxel-resistant tumor cell
lines were named ES2TR160 and TOV21GTR200. The
ES2TR160 and TOV21GTR200 cells were passaged weekly
and treated monthly with respective concentrations of pac-
litaxel to maintain their paclitaxel chemo-resistance.Generation of HIN-1 over-expressing ES2 and ES2TR160
cell lines
ES2 and ES2TR160 tumor cells were transfected with the
HIN-1 gene to generate HIN-1 over-expressing ES2 and
ES2TR160 transfectants as described previously [16].Reagents and antibodies
ECL Western blotting detection reagents were purchased
from Perkin Elmer (Boston, MA). Antibodies recognizing
HIN-1, mTOR, phospho-mTOR (Ser2448), AKT, phospho-
AKT (Ser473) (Thr308), and GAPDH were purchased from
Cell Signaling Technology (Beverly, MA). A Cell Titer 96-
well proliferation assay kit was obtained from Promega
(Madison, WI), and paclitaxel was obtained from Genetaxyl
Cream Less Company.MTT assays for cytotoxicity and proliferation assays
The sensitivities of various tumor cell lines to paclitaxel
were first assessed by MTT assay. Briefly, cells (4000
cells/well) in a 96-well plate were exposed to paclitaxel
at the indicated concentrations for 72 h at 37 °C. The
cells exposed only to the culture medium served as con-
trols. MTT at a final concentration of 0.5 mg/ml was
added to the cells and incubated at 37 °C for 3 h. At the
end of incubation, the cultured medium was removed
and 200 μl of DMSO (Sigma) was added to dissolve the
blue formazan crystals, and the optical density was mea-
sured at 490 nm using a universal microplate reader
(Elx800, Bio-tek Instruments). IC50 values (the concentra-
tion that produced a 50 % reduction in absorbance) were
analyzed and recorded. MTT assays were then performed
for the proliferation of tumor cells treated with 5-aza-2-dC
as described earlier. Briefly, ES2 and ESTR160 cells (1×104
cells/well in a 6-well plate) with or without 10 μM 5-aza-2-
dC (in growth media for 1, 3, 7, 10 or 14 days with 5 %
CO2 at 37 °C). 5 mg/ml of MTT solution was then added
to each well and incubated at 37 °C for 3 h. The medium
was then aspirated and replaced with solubilization solution
(DMSO). The plates were read on a Micro Elisa reader
(Anthos 2001) at 570 nm.
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by flow cytometry analysis
To evaluate the influence of 5-aza-2-dC on the cell cycle
of the tumor cells, the tumor cells were treated with or
without 10 μM 5-aza-2-dC for 3 days, washed with PBS,
and fixed with 70 % ethanol overnight at 4 °C. The cells
were then stained with propidium iodide (50 μg/ml) and
RNase A (100 μg/ml; Roth, Karlsruhe, Germany) for
20 min at 4 °C. The percentages of cells in the G0/G1
phase, S phase, and G2/M phase were determined using
a FACScan flow cytometer and analyzed by Cell Quest
software (Becton Dickinson, San Jose, CA).
Caspase-3/7 activity of the tumor cells treated with
paclitaxel and/or 5-aza-2-dC
Caspase-3/7 activity of the tumor cells was determined
quantitatively using a Caspase-Glo 3/7 assay kit (Promega)
according to the manufacturer’s instructions. Briefly, the
tumor cell lines were seeded and treated with paclitaxel or
5-aza-2-dC. After 24 h, the cells were lysed and lumino-
genic substrates specific for the caspase species were added.
Light emission was measured in a luminometer (Berthold
Technologies, Wildbad, Germany).
Genomic DNA and RNA extraction
Genomic DNA and RNA was extracted from the tumor
cell lines using a QIAamp tissue kit (Qiagen, Valencia, CA)
following the instructions of the manufacturer.
Sodium bisulfite treatment, sequencing, and methylation-
specific polymerase chain reaction analysis
Genomic DNA of the tumor cells was isolated using a
Genomic DNA kit (Geneaid Biotech, Bade City, Taiwan),
converted with sodium bisulfite using a CpGenome DNA
modification kit (Millipore, MA, USA), purified, and then
amplified by a PCR with DNA polymerase (ThermoHot-
Start 2× Gold PCR Master mix; Applied Biosystems) and
HIN-1-specific primers. The primer sequences for methyl-
ated HIN-1 were 5’-GAAGTTTCGTGGTTTTGTTCG-3’
(forward) and 5’-AAAACCTAAAATCCACGATCGAC-3’
(reverse), and the primer sets for unmethylated HIN-1
were 5’-TAAGAAGTTTTGTGGTTTTGTTTGG-3’ (for-
ward) and 5’-AAAAAACCTAAAATCCACAATCAAC-3’
(reverse). Bisulfite-modified Sss I (New England Biolabs,
MA)-treated normal lymphocyte DNA served as the
methylated control, and bisulfite-treated normal lympho-
cyte DNA as the unmethylated control. PCR products
were analyzed on 3 % agarose gels. A methylation specific-
PCR in a final volume of 20 μl was performed under the
following conditions: 95 °C for 10 min, followed by 40 cy-
cles at 95 °C for 30 s, 62 °C for 30 s, and 72 °C for 40 s,
with a final extension at 72 °C for 10 min and holding at
4 °C. The PCR products were purified and then directlysequenced using an Applied Biosystems ABI automated
DNA sequencer.
Quantitative real-time RT-PCR (QRT RT-PCR)
QRT RT-PCR was used to measure the MDR1, NANOG,
HIF-1α, HIF-2α, Snai2, TWIST1, and ABCG2 mRNA of
the tumor cell lines. GAPDH was used as the internal con-
trol. The QRT RT-PCR was performed in an ABI Prism
7300 Sequence Detection System (Applied Biosystems)
with a Taqman Gene Expression Assay (Hs00369360_g1)
under the following conditions: 2 min at 50 °C, 10 min at
95 °C, and a two-step cycle at 95 °C for 15 s and 60 °C for
1 min for 40 cycles with an additional dissociation curve.
The interpolated number (Ct) of cycles to reach a fixed
threshold above background noise was used to quantify
amplification.
5-aza-2-dC treatment and QRT RT-PCR of HIN-1 of the
tumor cell lines
The tumor cell lines were treated with or without 5-aza-2-
dC 10 μM, and renewed every 24 h. QRT RT-PCR was
used to measure the mRNA of HIN-1 as described earlier.
Immunohistochemistry
Formalin-fixed, paraffin-embedded specimens were sliced
by a microtome at a thickness of 3–5 um and placed on
coated slides. The tissue slides were then incubated with
purified goat anti-human UGRP2 (S-15) polyclonal Ab
(Santa Cruz Biotechnology) using a Thermo Scientific
Autostainer 360 (Thermo Fisher Scientific Inc., CA). The
immuno-reactive HIN-1 was scored semi-quantitatively,
and the expression was scored according to the intensity
as 0 or 1, 2 or 3 indicating no or low, intermediate or
strong immuno-reactivity, respectively. Tissues containing
more than 10 % neoplastic cells with a score of 2–3 inten-
sity were considered to be positive. The percentages of
each score in the neoplastic tissues were also recorded. If
less than 10 % of the neoplastic cells expressed HIN-1 the
expression was defined as being weak, and if more than
10 % of the neoplastic cells expressed HIN-1 the expres-
sion was defined as being strong. A pathologist not in-
volved in the present study evaluated the immunostaining
under blinded conditions.
Western blot analysis
Tumor cell lines were first treated with paclitaxel or 5-
aza-2-dC for 72 h. The cells were then collected and lysed
in PBS containing 1 % Triton X-100 using an ultrasonic
cell disruptor. The lysates were separated by SDS-PAGE
(12.5 %) and transferred to a PVDF membrane. The mem-
brane was blocked in blocking buffer (TBS containing
0.2 % Tween 20 and 1 % I-block (NEN)) and incubated
with the polyclonal antibodies separately for 1 h. A
purified rabbit anti-human GAPDH polyclonal Ab (Santa
Table 1 Clinico-pathological characteristics and HIN-1






Patient numbers 18 24




Early (I + II) 12 4 0.067b
Advanced (IIII + IV) 14 12
Tumor size (cm) 12.8 (6–21) 12.5 (3–23) 0.662a
OCCC ovarian clear cell carcinoma
aone-way ANOVA
bChi-square test
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time to normalize the signals generated from anti-HIN-1,
AKT, AKT p-Akt (Ser473), pAKT (Thr308), mTOR, and
pMTOR (Cell Signaling). After washing, alkaline phos-
phatase-conjugated anti-rabbit Ab (Vector Laboratories)
was applied. The membrane was washed and the bound
Abs was visualized by developing with NBT/BCIP as
chromogens.
In vivo animal experiments
NOD/SCID (NOD.CB17 Prkdc scid/Jnarl) mice were ob-
tained from the National Animal Center (Taipei, Taiwan)
and maintained in accordance with institutional policies.
All of the experiments were approved by the Institutional
Animal Care and Use Committee of Cathay General
Hospital. Five to 7-week-old NOD/SCID mice (n = 4)
were inoculated subcutaneously into the bilateral flank
with 1 × 107 of tumor cells treated with or without 10 μM
5-aza-2-dC for 3 days before inoculation. Tumor growth
was measured using calipers, and volumes were calculated
based on the modified ellipsoid formula (L ×W×W/2) at
the indicated time points. All of the experiments were
carried out in duplicate.
Statistical analysis
The median inhibitory concentrations (IC50) of paclitaxel
were calculated using Sigma Plot 8.0 software (SPSS, Inc.,
Chicago, IL). All numerical data were expressed as the
mean ± SD. Significance of the difference between two
groups was determined with the Mann–Whitney U test. A
p value less than 0.05 was considered to be statistically
significant.
Results
Characteristics of paclitaxel-sensitive and paclitaxel-
resistant cell lines in IC50, concentration, cell proliferation
and distribution of cell cycle
The IC50 concentrations of parental ES2 cells, TOV21G,
and their paclitaxel-resistant clones ES2TR160 and
TOV21GTR200 cells are shown in supplement Table 1.
The relative resistant indices of ES2TR160 vs. ES2 and
TOV21GTR200 vs. TVO21G were 9.36 and 228.3, re-
spectively. The cell morphologies of the cell lines
treated with paclitaxel are shown in Fig. 1a. Damaged
morphology was noted in the ES2 cells but not in the
ES2TR160 cells, including a decline in cell number, and
rounded cells undergoing hydropic and vacuolated changes
(Fig. 1a). Cell proliferation assays of ES2 and ES2TR160
cells treated with 160 nM of paclitaxel showed that the
cell proliferative activity of the ES2 cells was significantly
inhibited by paclitaxel compared with the ES2TR160 cells
(Fig. 1b).
The percentages of sub-G1, G1 and G2 phases among
the parental ES2 and ES2TR160 cells treated with differentconcentrations of paclitaxel were further analyzed. There
was no significant difference in the frequency of G1 (56.0 ±
1.8 % vs. 51.0 ± 1.4 %) or G2 (20.1 ± 0.9 % vs. 22.0 ± 1.3 %)
phase in between the ES2 and ES2TR160 cells before treat-
ment with paclitaxel (Fig. 1c), and the results were similar
between TOV21GTR200 and TOV21G cells (data not
shown). The percentage of the G2 phase in the ES2 cells
treated with 160 nM paclitaxel was significantly higher than
that in the ES2 cells without paclitaxel treatment (78.40 ±
3.35 % vs. 20.10 ± 0.88 %, p = 0.0001, one-way ANOVA)
(Fig. 1d). In contrast, the percentage of the G2 phase in
the ES2TR160 cells treated with 160 nM paclitaxel was
not significantly different compared with that in the
ES2TR160 cells without paclitaxel treatment (22.75 ±
0.44 % vs. 22.02 ± 1.27 %, p = 0.41, one-way ANOVA)
(Fig. 1d). These results indicated that G2-M phase arrest
was absent in the paclitaxel-resistant OCCC cells after
being treated with a cytotoxic drug.
Caspase activity in chemo-sensitive cells was higher than
in chemo-resistant cells when treated with paclitaxel
The caspase activity in the tumor cells treated with
paclitaxel was then evaluated. As shown in Fig. 2a, the
caspase-3/7 activity in the ES2 tumor cells was significantly
higher than in the ESTR160 tumor cells when treated with
paclitaxel (p < 0.001, one-way ANOVA).
Drug resistance-related genes in paclitaxel-resistant
tumor cells were more highly expressed than in
paclitaxel-sensitive tumor cells
The expression levels of drug resistance-related genes were
further evaluated by QRT RT-PCR. The expression levels
of MDR1 (Fig. 2b), NANOG (Fig. 2c), HIF-1α (Fig. 2c),
HIF-2α (Fig. 2c), Snai2 (Fig. 2c), TWIST1 (Fig. 2d), and
ABCG2 (Fig. 2e) were significantly higher in the paclitaxel-
resistant cell lines ES2TR160 and TOV21GTR200 than
in the paclitaxel-sensitive cell lines ES2 and TOV21G.
These results indicated that genes related to drug transport,
Fig. 1 a Morphologic changes of ES2 and ES2TR160 cells before and after paclitaxel treatment. Note: There were more floating ES2 cells than
floating ES2TR160 cells. b Cell growth curves of ES2 and ES2TR160 cells treated with or without 160 nM paclitaxel by MTT assays. c The
percentages of sub-G1, G1 and G2 phases among parental ES2 and ES2TR160 cells analyzed by flow cytometry. d The percentages of sub-G1,
G1 and G2 phases among parental ES2 and ES2TR160 cells treated with different concentrations of paclitaxel analyzed by flow cytometry
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onment, and epithelial-mesenchymal transition were highly
expressed in the paclitaxel-resistant tumor cells.
HIN-1 methylation of paclitaxel-resistant tumor cells could
be reversed by a demethylating agent
Changes in the methylation status of the HIN-1 gene in
paclitaxel-sensitive and resistant tumor cell lines were
evaluated by methylation-specific PCR. As shown in
Fig. 3a, the ES2TR160 cells showed higher methylation
of HIN-1 compared with the ES2 cells. We then tested
whether a demethylating agent could reverse the methyla-
tion of the HIN-1 gene and then reactivate the expression
of HIN-1. The methylation of HIN-1 in the ES2TR160
cells was reduced with 5-aza-2-dC treatment (Fig. 3a). In
addition, the expression levels of HIN-1 in the 5-aza-2-
deoxycytidine-treated groups were significantly increased
compared with those in the PBS-treated groups in both
the ES2 and ES2TR160 cell lines (Fig. 3b and c). These re-
sults indicated that the expression of HIN-1 in paclitaxel-resistant OCCC cells was lower than that in paclitaxel-
sensitive OCCC cells due to the methylation of HIN-1. In
addition, a demethylating agent could reverse the methyla-
tion of HIN-1 and restore its expression.
Paclitaxel-resistant OCCC tissues expressed lower levels of
HIN-1 than paclitaxel-sensitive OCCC tissues
The representative photographs of HIN-1 immuno-
reactivity in OCCC tumor tissues by immunohistochemical
staining are shown in Fig. 4 (Fig. 4a: high expression of
HIN-1, Fig. 4b: low expression of HIN-1). Fourteen
(33.3 %) of 42 patients were paclitaxel-resistant and 28
(66.7 %) were paclitaxel-sensitive. Among the 14 paclitaxel-
resistant OCCC tissues, 13 (93.8 %) showed a weak HIN-1
protein expression. In contrast, among the 28 paclitaxel-
sensitive OCCC tissues, only 17 (62.8 %) showed a weak
HIN-1 protein expression. The paclitaxel-resistant OCCC
tissues had a significantly higher percentage of weak HIN-1
protein expression than the paclitaxel-sensitive OCCC tis-
sues (93.8 % vs. 62.8 %, p = 0.03, chi-square test) (Fig. 4c).
Fig. 2 a Caspase-3/7 activity in both ES2 and ESTR160 cells with or without paclitaxel treatment. The expression levels of (b) MDR1, (c) NANOG,
HIF-1α, HIF-2α, and Snai2, (d) TWIST1, and (e) ABCG2 in ES2 and TOV21G parental cells and their derived paclitaxel-resistant ES2TR160 and
TOV21GTR200 cells by QRT-PCR
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strongly associated with the response to paclitaxel of the
OCCC patients. We retrospectively reviewed and analyzed
our 42 OCCC patients. Among the analyzed 26 advanced
OCCC tissues, 14 (54 %) samples of advanced OCCCs
showed scored as HIN-1 weak staining (0 or +1 immuno-
reactivity), and 12 (46 %) were HIN-1 strong staining (+2
or +3 immuno-reactivity). In contrast, among the 16 early
stage OCCCs, 12 (75 %) tumors were scored as 0 or +1
immuno-reactivity and 4 (25 %) were +2 or +3. The
percentage of HIN-1 immuno-reactivity at 0 or +1 was
significantly higher in advanced OCCCs than in early
stage (54 % vs 25 %, p = 0.067). These results indicate
that loss of HIN-1 expression has a trend towards ad-
vanced OCCC tumors. However, HIN-1 expression
levels among tumors are not associated with tumor size
(p = 0.662) (Table 1).
HIN-1 reduced in vivo tumor growth
To further examine whether HIN-1 could inhibit the
growth of paclitaxel-resistant OCCC tumor cells, in vivosubcutaneous xenograft experiments were performed. Mice
receiving ES2TR160 cells expressing high concentrations of
HIN-1 had a smaller tumor size compared with those chal-
lenged with ES2TR160 parental cells (Fig. 5a) (ES2TR160
cells with high expressions of HIN-1 vs. ES2TR160 mock
cells; day 21, 133.76 vs. 211.74 mm3, p = 0.036; day 27,
266.55 vs. 484.92 mm3, p = 0.008, both by the Student’s t
test). These results indicated that HIN-1 could inhibit the
in vivo growth of paclitaxel-resistant OCCC tumor cells.
5-Aza-2-dC inhibited the in vivo tumor growth of
paclitaxel-sensitive and resistant OCCC cell lines
The in vivo growth inhibitory effect of 5-aza-2-dC on
OCCC tumor cells was further evaluated. As shown in
Fig. 5b, the mice receiving ES2 or TOV21G parental
tumor cells treated with 5-aza-2-dC had smaller tumor
sizes compared with those treated with PBS. The mean
tumor size of the ES2 tumor cells treated with 5-aza-2-dC
was smaller than that of ES2 tumor cells treated with PBS
(day 37, 217.8 vs. 1764.1 mm3, p < 0.01, Student’s t test). In
addition, the mice challenged with ES2TR tumor cells
Fig. 3 a Changes of methylation status of the HIN-1 gene detected by methylation-specific PCR in parental ES2 cells and the derived
paclitaxel-resistant ES2TR160 cells before and after 5-aza-2-dC treatment for 3 or 6 days. M represents methylation and U represents
unmethylation. b Representative figure of HIN-1 mRNA expression in ES2 and ES2TR160 cells treated with or without 5-aza-2-dC for 3 or
6 days. c Bar figure of the folds of HIN-1 mRNA expression in the ES2 and ES2TR160 cells treated with or without 5-aza-2-dC for 6 days
Fig. 4 Representative immunohistochemical staining of HIN-1 in OCCC cancerous tissues. a Weak expression of HIN-1. b High expression of
HIN-1. Note: The high HIN-1 expression was noted in the cytoplasm of the neoplastic cells (arrows). c Bar figures of the percentage of weak
and strong HIN-1 protein expression in paclitaxel-resistant and paclitaxel-sensitive OCCC tissues
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Fig. 5 a The average tumor size in xenograft mice after subcutaneous inoculation of 1 × 106 cells of ES2TR160 mock or ES2TR160 HIN-1 transfectants.
b The average tumor sizes in xenograft mice after subcutaneous inoculation of 1 × 106 of ES2 or TOV21G cells with or without 5-aza-2-dC treatment.
c The average tumor sizes in xenograft mice with subcutaneous inoculation of 1 × 106 of ES2TR160 cells with or without 5-aza-2-dC treatment
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lenged with ES2TR tumor cells treated with 5-aza-2-dC
had died 35 days after tumor challenge (Fig. 5c). These
results suggest that 5-aza-2-dC effectively inhibited the
growth of both paclitaxel-sensitive and resistant OCCC
tumor cells.
5-Aza-2-dC inhibited the proliferative activities of both
paclitaxel-sensitive and resistant OCCC cell lines in vitro
The effects of 5-aza-2-dC on the growth of paclitaxel-
sensitive and paclitaxel-resistant OCCC cells were exam-
ined by MTT assays. The results showed that 5-aza-2-dC
inhibited cell growth by 70 % in both ES2 and ES2TR160
tumor cells (Fig. 6a). In addition, 5-aza-2-dC significantly
reduced the percentages of the G1 phase (66.4 % ± 1.1 to
19.9 % ± 1.8 % in the ES2 cells, p < 0.001; 50.8 % ± 2.7 to
22.0 % ± 2.4 % in the ES2TR160 cells, p < 0.001, Student’s t
test), but significantly increased the percentages of the G2
phase (14.4 % ± 0.5 to 39.0 % ± 1.7 % in the ES2 cells, p <
0.001; 17.4 % ± 0.6 to 34.8 % ± 1.8 % in the ES2TR160cells, p < 0.01, Student’s t test) after 3 days of treatment
(Fig. 6b). Furthermore, 5-aza-2-dC also reduced the
caspase-3/7 activity in ES2 cells but not in ES2TR160
cells (Fig. 6c).
HIN-1-AKT-mTOR signaling pathway was involved in the
paclitaxel-treated OCCC tumor cells
The molecules involved in the signaling pathways associ-
ated with paclitaxel-related drug resistance were further
evaluated by immunoblotting analysis. The expressions
of phospho-AKT473 and phospho-mTOR were signifi-
cantly increased in the ES2TR160 cells in parallel to
the decrease in HIN-1 expression compared to the
ES2 parental cells (Fig. 7a). However, the expressions
of phospho-AKT at Ser473 and Thr308 and phospho-
mTOR were decreased in the ES-2TR160 tumor cells
with high expressions of HIN-1 (Fig. 7a). In addition,
5-aza-2-dC also decreased the expressions of phospho-
AKT at Ser473 and Thr308 and phospho-mTOR. Whereas,
an increased HIN-1 expression was observed in the 5-aza-
Fig. 6 a The effect of 10 μM or 100 μM of 5-aza-2-dC on in vitro cell growth of ES2 and ES2TR160 cells by MTT assay. b The percentages of G1
and G2 phases in both ES2 and ES2TR160 cells with 5-aza-2-dC treatment for 3 days. c The caspase-3/7 activity in both ES2 and ES2TR160 cells
with or without 5-aza-2-dC treatment
Fig. 7 a Changes in HIN-1, p-AKT (Thr308), p-AKT (Ser473), and
p-mTOR protein expressions in ES2 mock, ES2TR160 mock, and
ES2TR160HIN-1 transfectants by Western blotting. 1: ES2 mock, 2:
ES2TR160 mock, 3: ES2TR160HIN-1 transfectant. b HIN-1, p-AKT
(Thr308), p-AKT (Ser473), and p-mTOR protein expressions in ES2 and
ES2TR160 cells treated with or without 5-aza-2-dC by Western blotting
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These results demonstrated that 5-aza-2-dC may increase
the expression of HIN-1 by decreasing the AKT-mTOR ex-
pression in paclitaxel-resistant OCCC tumor cells.
Discussion
Aberrations in DNA methylation are involved in tumor
progression and the acquisition of drug resistance. To
investigate whether paclitaxel selects preferentially for
DNA methylation in chemo-resistant OCCC cell lines,
we used MS-MLPA to detect 40 tumor suppressing genes
(TSGs) in ES2 and TOV21G parental and resistant cells.
We found changes in methylation of the HIN-1 gene in
ES2TR160 and TV21GTR200 paclitaxel-resistant cells,
and this may be involved in the mechanism of paclitaxel
resistance (data not shown). Significantly more paclitaxel-
resistant OCCC cells had a low expression of the HIN-1
protein compared to the paclitaxel-sensitive OCCC
cells (93.8 % vs. 62.8 %, p = 0.03), suggesting that down-
regulation of the expression of HIN-1 is strongly correlated
with paclitaxel-resistant OCCC tumors. Over-expression of
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of paclitaxel-resistant ES2TR160 tumor cells, which is
consistent with promoter methylation of HIN-1 and the
poor outcomes of patients with OCCC [16]. 5-Aza-2-dC
inhibited tumor growth by demethylating aberrantly
methylated TSGs and maintaining function, presumably
through restoration of HIN-1 expression with a decrease in
AKT-mTOR expression. Furthermore, 5-aza-2-dC inhibited
growth of ES2 and ES2TR160 cells mainly by inhibiting
the G2M phase, but without increasing apoptosis and
autophagy (Fig. 6). These results support the concept
that 5-aza-2-dC can inhibit tumor growth of OCCC
partly through affecting the HIN-1-related AKT-mTOR
signaling pathway, and this may be a promising therapy
for the management of primary or recurrent OCCC.
Clinical trials are warranted to test this hypothesis.
OCCC is a chemo-resistant tumor. Experimental evi-
dence has suggested different mechanisms by which tumor
cells can develop resistance to taxanes, including excluding
taxane from cells by ATP-binding cassette transporters, the
expression of certain tubulin isoforms and microtubule as-
sociated proteins, tubulin gene mutations, alterations in
survival or mitotic check point signaling, and methylation-
associated Has-miR-9 deregulation [17, 18]. ES2TR160 and
TOV21GTR200 cancer cell lines did not acquire paclitaxel
resistance via somatic mutations in tubulin genes, as those
nicely reviewed in previous report [18]. In the present
study, however, G2-M phase arrest was absent in the
paclitaxel-resistant OCCC cells even though these cells
were under paclitaxel treatment. Our results support
that the mechanism of paclitaxel resistance in OCCC
may involve the drug transporter gene, cancer stem cell
characteristics, hypoxic tumor microenvironment, and
epithelial-mesenchymal transition.
Methylation of HIN-1 is involved in the chemo-
resistance of OCCC. Importantly, the reversal of HIN-1
epigenetic silencing by demethylation or over-expression
of the HIN-1 gene was demonstrated to resensitize tumor
cells to paclitaxel treatment in vitro and in vivo. We also
observed that CpG sites at probe 12956 of the HIN-1 gene
were hypomethylated in ES2 and TOV21G cells, whereas
they became hypermethylated following step-wise ex-
posure to paclitaxel in ES2TR160 and TOV21GTR200
cells as confirmed by methylation-specific PCR, suggesting
that hypermethylation occurs in acquired paclitaxel
chemo-resistance (data not shown).
We previously showed that the ectopic expression of
the HIN-1 gene increases paclitaxel sensitivity, partly
through the Akt pathway [16]. The SCGB3A1 gene, also
called HIN-1 (high in normal-1), encodes a small se-
creted protein, secretoglobin 3A1 which is a member of
the secretoglobin family [19]. Recent reports have shown
that HIN-1 expression is down-regulated in the majority of
lung, breast, prostate, pancreatic, colorectal, testicular andnasopharyngeal cancers, and that this down-regulation is
associated with hypermethylation of the HIN-1 promoter
[20–24]. Thus, silencing of HIN-1 expression by methyla-
tion is an early and frequent event in multiple human types
of cancer, and is functionally relevant to tumorigenesis [22].
These findings together with in vitro data on growth inhib-
ition and AKT activation in breast cancer suggest that
HIN-1 may be a candidate tumor suppressor gene [24].
Clinical studies have shown that a low dose of decita-
bine can alter the DNA methylation of genes and cancer
pathways, thereby restoring sensitivity to carboplatin in
heavily pretreated ovarian cancer patients who progressed
or recurred within 6 months after platinum-based chemo-
therapy, resulting in a high response rate and prolonged
progression free survival [12]. The selective epigenetic dis-
ruption of distinct biological pathways has been observed
during the development of platinum resistance in patients
with ovarian cancer. Hypermethylation-mediated repres-
sion of cell adhesion and tight junction pathways, and
hypomethylation-mediated activation of the cell growth-
promoting pathways PI3K/Akt and TGF-beta, and cell
cycle progression may contribute to the onset of chemo-
resistance in ovarian cancer cells [15].
The PI3K/Akt pathway has been shown to contribute
to cisplatin resistance by promoting cell proliferation and
increasing drug metabolism and resistance to apoptosis
[25, 26]. Paclitaxel activates AKT and mTORC1 signaling
which act as resistant factors and protect cancer cells from
death/apoptosis [27, 28]. The mammalian target of rapa-
mycin (mTOR) has been identified to be a downstream
target of the PI3K/Akt pathway, and it has emerged as
a critical effector in cell signaling pathways commonly
deregulated in human cancers. mTOR has been reported
to be phosphorylated and activated in endometriosis and
OCCC specimens [29]. This leads to phosphorylation
of downstream targets, p70S6K and 4E-BP1, and the
subsequent enhanced translation of mRNA that is critical
for cell cycle progression and proliferation. Recently, a
therapeutic strategy targeting the mTOR-HIF-1α-VEGF
pathway in OCCC has been proposed based on the finding
that p-mTOR expression is more prominent in OCCC
than ovarian serous carcinoma [30]. After treatment with
an analogue of rapamycin (everolimus), the expressions of
p-mTOR, HIF-1α and VEGF were shown to be sharply
decreased [30].
In this study, 5-aza-2-dC not only decreased phospho-
AKT at Thr308 and Ser473 and phospho-mTOR, but
also restored HIN-1 expression in paclitaxel-resistant
cells in vitro. In addition, treatment with 10 μM 5-aza-2-
dC also inhibited the growth of both ES2 and ES2TR160
tumor cells (Fig. 6a). Furthermore, 5-aza-2-dC treatment
significantly reduced the percentage of the G1 phase in
both ES2 and ES2TR160 cells after 3 days of treatment.
These results support that 5-aza-2-dC can overcome
Ho et al. BMC Cancer  (2015) 15:789 Page 11 of 12paclitaxel drug resistance and inhibit tumor growth of
paclitaxel-resistant OCCC partly through affecting the
HIN-1-AKT-mTOR signaling pathway.
Taken together, a demethylating agent can restore
the HIN-1 expression in paclitaxel-resistant OCCC
cells through the HIN-1-AKT-mTOR signaling pathway
and then inhibit in vivo tumor growth. Restoration of
HIN-1 by a demethylating agent may be a potential
strategy for the treatment of paclitaxel-resistant OCCC.
Conclusion
This is the first study to show that a demethylating agent
could inhibit tumor growth of OCCC in vivo and in vitro.
Treatment with 5-aza-2-dC remarkably inhibited ES2-
derived tumor growth by 90-100 % compared to the
controls, in both ES2 (paclitaxel-sensitive) and ES2TR160
(paclitaxel-resistant) cells treated with 5-aza-2-dC for
3 days prior to subcutaneous inoculation in mice. We con-
cluded that 5-aza-2-dC has a remarkable anti-tumor effect
as a single agent in OCCC.
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